MORRISVILLE – Triangle-based Liquidia has struck an exclusive licensing deal for North America with Taiwan-based Pharmosa Biophram around a new drug to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It’s now in clinical trial.
Liquidia is paying a $10 million upfront fee for the rights.
Read the full announcement here.
